{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T12:04:27Z","timestamp":1767182667506,"version":"3.41.0"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Radiation Oncology"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.semradonc.2025.04.011","type":"journal-article","created":{"date-parts":[[2025,6,12]],"date-time":"2025-06-12T23:15:47Z","timestamp":1749770147000},"page":"433-438","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach"],"prefix":"10.1016","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5176-0507","authenticated-orcid":false,"given":"Gunhild","family":"von Amsberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Moritz","family":"Kaune","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anja","family":"Coym","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadja","family":"Strewinsky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Falkenbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan Lukas","family":"Hohenhorst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Derya","family":"Tilki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergey","family":"Dyshlovoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semradonc.2025.04.011_bib0001","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","article-title":"Oligometastases","volume":"13","author":"Hellman","year":"1995","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.011_bib0002","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.011_bib0003","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.011_bib0004","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.011_bib0005","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.euo.2019.07.010","article-title":"Oligometastatic prostate cancer: results of a Dutch multidisciplinary consensus meeting","volume":"3","author":"Aluwini","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.011_bib0006","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.011_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms7605","article-title":"Tracking the origins and drivers of subclonal metastatic expansion in prostate cancer","volume":"6","author":"Hong","year":"2015","journal-title":"Nat Commun"},{"issue":"9","key":"10.1016\/j.semradonc.2025.04.011_bib0008","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.2967\/jnumed.118.213470","article-title":"Oligometastatic prostate cancer: molecular imaging and clinical management implications in the era of precision oncology","volume":"59","author":"Jadvar","year":"2018","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.011_bib0009","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1097\/MOU.0000000000000434","article-title":"The biology of prostate cancer metastases: does oligo differ from polymetastatic?","volume":"27","author":"Sonpavde","year":"2017","journal-title":"Curr Opin Urol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.011_bib0010","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.18632\/oncotarget.2920","article-title":"14q32-encoded microRNAs mediate an oligometastatic phenotype","volume":"6","author":"Uppal","year":"2015","journal-title":"Oncotarget"},{"issue":"14","key":"10.1016\/j.semradonc.2025.04.011_bib0011","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1002\/cncr.30058","article-title":"Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT)","volume":"122","author":"Wong","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.semradonc.2025.04.011_bib0012","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1038\/s41467-018-04278-6","article-title":"Integrated molecular subtyping defines a curable oligometastatic state in colorectal liver metastasis","volume":"9","author":"Pitroda","year":"2018","journal-title":"Nat Commun"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.011_bib0013","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1007\/s00345-018-2609-8","article-title":"Discovery and validation of a serum microRNA signature to characterize oligo- and polymetastatic prostate cancer: not ready for prime time","volume":"37","author":"Dhondt","year":"2019","journal-title":"World J Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.011_bib0014","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.eururo.2020.12.040","article-title":"The mutational landscape of metastatic castration-sensitive prostate cancer: the spectrum theory revisited","volume":"80","author":"Deek","year":"2021","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.semradonc.2025.04.011_bib0015","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1016\/j.ijrobp.2022.12.006","article-title":"WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer","volume":"115","author":"Sutera","year":"2023","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.semradonc.2025.04.011_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110618","article-title":"Validation of an artificial intelligence-based prognostic biomarker in patients with oligometastatic castration-sensitive prostate cancer","volume":"202","author":"Wang","year":"2025","journal-title":"Radiother Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.011_bib0017","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-24-3027","article-title":"PSMA+ extracellular vesicles are a biomarker for SABR in oligorecurrent prostate cancer analysis from the STOMP-like and ORIOLE trial cohorts","volume":"31","author":"Andrews","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"suppl 5","key":"10.1016\/j.semradonc.2025.04.011_bib0018","article-title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET collaboration","volume":"43","author":"Tang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.011_bib0019","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2019.37.7_suppl.141","article-title":"Final analysis of phase III LATITUDE study in patients (pts) with newly diagnosed high-risk metastatic castration-na\u00efve prostate cancer (NDx-HR mCNPC) treated with abiraterone acetate + prednisone (AA+P) added to androgen deprivation therapy (ADT)","volume":"37","author":"Fizazi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.semradonc.2025.04.011_bib0020","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.eururo.2021.05.016","article-title":"Overall survival of men with metachronous metastatic hormone-sensitive prostate cancer treated with enzalutamide and androgen deprivation therapy","volume":"80","author":"Sweeney","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.semradonc.2025.04.011_bib0021","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejca.2023.113290","article-title":"Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: a subgroup analysis of the randomised clinical TITAN study","volume":"193","author":"Merseburger","year":"2023","journal-title":"Eur J Cancer"},{"issue":"2","key":"10.1016\/j.semradonc.2025.04.011_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.eururo.2023.04.002","article-title":"The efficacy of enzalutamide plus androgen deprivation therapy in oligometastatic hormone-sensitive prostate cancer: a post hoc analysis of ARCHES","volume":"84","author":"Armstrong","year":"2023","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.semradonc.2025.04.011_bib0023","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"20","key":"10.1016\/j.semradonc.2025.04.011_bib0024","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and Docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.011_bib0025","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1200\/jco.2015.33.7_suppl.140","article-title":"Androgen deprivation therapy (ADT) plus docetaxel (D) versus ADT alone for hormone-na\u00efve metastatic prostate cancer (PCa): long-term analysis of the GETUG-AFU 15 phase III trial","volume":"33","author":"Gravis","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.semradonc.2025.04.011_bib0026","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.5081","article-title":"Eight-year survival rates by baseline prognostic groups in patients with metastatic hormone-sensitive prostate cancer (mHSPC): an analysis from the ECOG-ACRIN 3805 (CHAARTED) trial","volume":"40","author":"Tripathi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.011_bib0027","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.eururo.2019.08.006","article-title":"Abiraterone in \"high-\" and \"low-risk\" metastatic hormone-sensitive prostate cancer","volume":"76","author":"Hoyle","year":"2019","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.semradonc.2025.04.011_bib0028","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.011_bib0029","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.semradonc.2025.04.011_bib0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.ejca.2023.02.018","article-title":"Management of patients with advanced prostate cancer-metastatic and\/or castration-resistant prostate cancer: report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022","volume":"185","author":"Gillessen","year":"2023","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.semradonc.2025.04.011_bib0031","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/j.eururo.2024.01.021","article-title":"Systemic and tumor-directed therapy for oligorecurrent metastatic prostate cancer (SATURN): primary endpoint results from a phase 2 clinical trial","volume":"85","author":"Nikitas","year":"2024","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.semradonc.2025.04.011_bib0032","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"}],"container-title":["Seminars in Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000396?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053429625000396?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T19:06:04Z","timestamp":1750791964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053429625000396"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1053429625000396"],"URL":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.011","relation":{},"ISSN":["1053-4296"],"issn-type":[{"type":"print","value":"1053-4296"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Debate 3: Oligometastatic Hormone Sensitive Prostate Cancer Management: Systemic Therapy Approach","name":"articletitle","label":"Article Title"},{"value":"Seminars in Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semradonc.2025.04.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}